B7-H4

B7-H4

B7-H4 Molekülinformation

Molecule Name
V-set domain-containing T-cell activation inhibitor 1
Molekülalias
B7-H4,VTCN1,B7S1,B7h.5
Drug Development Progress
Anzahl der klinischen Arzneimittel11
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Molekülhintergrund
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

B7-H4 Produktliste

Species
  • Human(4)
  • Mouse(3)
  • Cynomolgus / Rhesus macaque(2)
  • Canine(1)
  • Rat(1)
Tag
  • His Tag(7)
  • His Tag & Avi Tag(3)
  • Fc Tag(1)
Host
  • HEK293(11)
Conjugate
  • Unconjugated(6)
  • Biotin-labeled(4)
  • Azide Labeled(1)
Grade
  • RUO(11)
Low Endotoxin
  • Yes(5)
  • No(6)
You Have Viewed 1-10 Of 11 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Puxitatug SamrotecanAZD8205; AZD-8205Phase 3 ClinicalAstrazeneca Plc
Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
Mocertatug RezetecanHS-20089; GSK-5733584; GSK5733584Phase 3 ClinicalShanghai Hansoh Biomedical Co Ltd
Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
ABL-103ABL-103Phase 2 ClinicalAbl Bio Inc, Handok Inc
Solid tumours
Details
MHB-009CMHB-009C; MHB009CPhase 2 ClinicalMinghui Pharmaceutical (Hangzhou) Co Ltd
Solid tumours
Details
GEN-1047GEN-1047Phase 2 ClinicalGenmab A/S
Endometrial Neoplasms
Details
DB-1312BG-C9074; DB-1312Phase 1 ClinicalDuality Biologics (Suzhou) Co Ltd
Solid tumours
Details
LNCB-74LNCB-74; LNCB74; LCB41APhase 1 ClinicalLigaChem Biosciences Inc, Nextcure Inc
Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours
Details
XKH-002XKH-002; XKH002Phase 1 ClinicalBeijing Kanova Biomedical Technology Co Ltd, Zhejiang Kanova Biopharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
Felmetatug vedotinSGN-B7H4V; PF-08046048; SGN-B-7H-4V; SGNB-7H4V; SGNB-7H-4VPhase 1 ClinicalSeagen Inc
Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
Emiltatug LedadotinXMT-1660Phase 1 ClinicalMersana Therapeutics Inc
Abdominal Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms
Details
HBM-7008HBM7008; HBM-7008; R-7008; CLN-418Phase 1 ClinicalHarbour Biomed
Solid tumours
Details
Customer Reviews
  • 1***12019-11-16
    We purchased total of 600ug of this biotin-labeled antigen for liquid phase panning and antibody screening of affinity maturation. This antigen has good stability, high quality, and high repeatability for each experiment. Using this antigen, we screened high-affinity antibodies against this target. And using this antigen for screening of affinity maturation, we obtained antibodies with 10-times increased affinity. I highly recommended this product.